Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Employees - 36, CEO - Dirk Thye, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -6.9, Piotroski Score(max is 10): 2, Working Capital: $3158000, Total Assets: $109899000, Retained Earnings: $-420993000, EBIT: -54855000, Total Liabilities: $108840000, Revenue: $0

- Current Price $ - Analyst Target Price $